Marieke van Son

39 RADICAL VS. FOCAL TREATMENT FOR LOCALIZED PROSTATE CANCER 17. Oishi M, Gill IS, Tafuri A, et al. Hemi- gland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Out- comes at 5 Years. The Journal of urolo- gy. 2019;202(6):1188-1198. 18. Hamdy FC, Elliott D, le Conte S, et al. Par- tial ablation versus radical prostatecto- my in intermediate-risk prostate cancer: the PART feasibility RCT. Health tech- nology assessment. 2018;22(52):1-96. 19. AhmedHU, BergeV, BottomleyD, et al. Can we deliver randomized trials of focal ther- apy in prostate cancer? Nature reviews Clinical oncology. 2014;11(8):482-491. 20. Reddy D, Shah TT, Dudderidge T, et al. Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II paral- lel Randomised Control Trial. Contem- porary clinical trials. 2020:105999. 21. Shah TT, Reddy D, Peters M, et al. Focal therapy compared to radical prosta- tectomy for non-metastatic prostate cancer: a propensity score-matched study. Prostate cancer and prostatic diseases. 2021. 22. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297. 23. Diaz A, Roach M, 3rd, Marquez C, et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;30(2):323-329. 24. Peters M, van Son MJ, Moerland MA, et al. MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study. Int J Radiat Oncol Biol Phys. 2019;104(5):1045-1053. 25. Li L, Greene T. A weighting analogue to pair matching in propensity score anal- ysis. Int J Biostat. 2013;9(2):215-234. 26. Yoshida K, Hernandez-Diaz S, Sol- omon DH, et al. Matching Weights to Simultaneously Compare Three Treatment Groups: Comparison to Three-way Matching. Epidemiology. 2017;28(3):387-395. 27. Austin PC. An Introduction to Propen- sity Score Methods for Reducing the Effects of Confounding in Observa- tional Studies. Multivariate Behav Res. 2011;46(3):399-424. 28. Simopoulos DN, Sisk AE, Jr., Priester A, et al. Cancer core length from target- ed biopsy: an index of prostate cancer volume and pathological stage. BJU in- ternational. 2019;124(2):275-281. 29. Nascimento B, Miranda EP, Jenkins LC, Benfante N, Schofield EA, Mulhall JP. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer. The journal of sexual medicine. 2019;16(6):872-879. 30. Nam W, Choi SY, Yoo SJ, et al. Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer. Investig Clin Urol. 2018;59(1):18-24. 31. Akakura K, Suzuki H, Ichikawa T, et al. A randomized trial comparing radical pros- tatectomy plus endocrine therapy versus external beam radiotherapy plus endo- crine therapy for locally advanced pros- tate cancer: results at median follow-up of 102 months. Japanese journal of clinical oncology. 2006;36(12):789-793. 32. Taguchi S, Shiraishi K, Fukuhara H. Updated evidence on oncological out- comes of surgery versus external beam radiotherapy for localized prostate cancer. Japanese journal of clinical on- cology. 2020;50(9):963-969. 33. Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guide- lines in Oncology. Journal of the Na- tional Comprehensive Cancer Network : JNCCN. 2019;17(5):479-505. 2